China now dominates the global humanoid robot start-up landscape by the most rigorous measure available, patent quality, with six Chinese firms ranked among the world’s ten most innovative humanoid robot companies, according to a new LexisNexis analysis published Tuesday. The timing is pointed: the rankings landed on the same day the Trump administration announced a ban on new imports of Chinese humanoid and quadruped robots, framing the two developments as a snapshot of a race that Washington may already be losing on the metrics that matter most.
The LexisNexis Patent Asset Index, which measures not just the volume of patents filed but their technological value, market coverage, and the degree to which subsequent innovations build upon them, placed Shanghai-based Fourier and AgiBot, Shenzhen-based LimX Dynamics and Pudu Robotics, and Hangzhou-based Unitree Robotics in the top five positions. Shenzhen’s Leju Robot ranked ninth. Only three US firms made the cut: Figure AI (sixth), Apptronik (eighth), and Agility Robotics (tenth). Germany’s Agile Robots was the sole European entrant, placing seventh.
China’s Patent Surge: Scale and Quality Together
The LexisNexis study drew on more than 26,000 patent families across three core technology areas, interaction systems, morphology, and control and planning architectures, that define what makes a humanoid robot functional, adaptive, and autonomous. The results show a decade-long acceleration that is now compounding.
Over the past ten years, patent activity from China-based inventors grew approximately twofold in interaction systems, 2.5 times in morphology, and fivefold in control and planning architectures. By the end of 2025, China accounted for 73% of the active morphology-related patent portfolio globally, and 63% of its overall portfolio strength by the Patent Asset Index metric. The study was explicit that these figures reflect not just filing volume, a metric where China has long been criticized for quantity over quality, but the downstream value of those inventions as measured by citations, scope, and commercial applicability.
The United States, by contrast, punches above its weight on quality relative to volume. US-based inventors account for only 5% of active morphology-related patent families, yet contribute 11% of global portfolio strength, more than twice their share by count. The average quality of US patents in the field remains the highest of any country. But that quality premium is being eroded by China’s sheer scale of output, and the gap in absolute portfolio strength is widening every year.
(Related: China’s Humanoid Robot Models Exceed 400, Surpassing Half of Global Total)
The FCC Ban in Context
The LexisNexis rankings arrive one day after the Federal Communications Commission moved to ban imports of new Chinese humanoid and quadruped robots, citing national security concerns about data collection capabilities and the risk that Chinese-made robots could be used to surveil sensitive US infrastructure. As EastFrontier reported, the FCC ban covers new imports only, robots already deployed in the US are unaffected, and it exempts certain industrial categories pending further review.
The juxtaposition is uncomfortable for Washington. The ban is a defensive measure designed to slow Chinese penetration of the US market. The patent data suggests that on the innovation dimension, the one that determines who builds the next generation of robots, China’s lead is structural, not circumstantial. Six of the ten most innovative humanoid robot start-ups in the world are Chinese, they hold the top five positions, and their patent portfolios are growing faster than their American counterparts by every measure the LexisNexis methodology captures.
The three US firms in the top ten (Figure AI, Apptronik, and Agility Robotics) are all venture-backed start-ups that have attracted significant capital and media attention. Figure AI, which counts Microsoft and OpenAI among its backers, has been particularly prominent. But none of them crack the top five, and the gap between the US cohort and the Chinese leaders in patent portfolio strength is substantial.
What the Rankings Mean for the Commercial Race
Patent strength is a leading indicator of commercial competitiveness, not a guarantee of it. China’s dominance in humanoid robot patents does not automatically translate into market dominance, commercialization requires manufacturing scale, software ecosystems, customer relationships, and the ability to deploy robots in real-world environments reliably and cost-effectively. On some of those dimensions, US firms retain advantages, particularly in software and AI integration.
But the patent data does capture something important: where the underlying R&D investment is going, and who is building the defensible technological positions that will matter when the humanoid robot market scales from tens of thousands of units to millions. The LexisNexis analysis covers more than 26,000 patent families, and its methodology is designed to filter out low-value filings — making the Chinese dominance in the rankings a signal worth taking seriously.
(Related: Morgan Stanley Doubles China Humanoid Robot Forecast Again — 50,000 Units Expected in 2026)
The broader context is one of accelerating divergence. China’s government has made humanoid robotics a strategic priority, with dedicated standardization work, deployment mandates in industrial environments, and state-backed funding flowing to the sector. The result is a feedback loop: government support drives patent activity, patent activity drives commercial credibility, commercial credibility attracts more capital, and more capital drives more R&D. The LexisNexis rankings are one output of that loop, and they suggest it is running faster than Washington’s countermeasures can keep up with.
For US policymakers, the challenge is that import bans address the symptom, Chinese robots in American facilities, without addressing the cause: a structural innovation gap that is widening in China’s favor. Closing that gap would require a sustained, coordinated investment in humanoid robotics R&D comparable to what China has been doing for a decade. Whether the political will and funding exist to mount that response, at the scale and speed required, remains the central unanswered question in the US-China robotics competition.